Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

This study is testing a combination of azacitidine (a chemotherapy drug) plus a PD-1 checkpoint inhibitor (an immunotherapy) for people with Hodgkin lymphoma that has come back or stopped responding to treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with Hodgkin lymphoma that has relapsed (came back) or is refractory (did not respond) after at least one prior treatment - Your blood counts meet minimum thresholds (neutrophils, platelets, hemoglobin) - Your estimated life expectancy is at least 3 months **You may NOT be eligible if...** - You have an active serious infection requiring IV antibiotics - You have severe heart, liver, kidney, or metabolic disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.